Neovacs (ALNEV)

Business description

Neovacs is a French biotech company focused on the development of active immunotherapies for the treatment of lupus and dermatomyositis. A Phase II programme with IFN-alpha-Kinoid in lupus is underway.

Stock data

Market cap.€36.1m
Last close€0.84
High / Low (52 weeks)€1.2 / €0.7
Stock market listingAL
Forecast net cash (€m)1.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.5)(4.5)(27.9)
Relative *(9.3)(12.5)(37.9)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic BB Healthcare Trust
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
Biondvax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Collplant Holdings Consort Medical
Corium International Crescendo
Crossject Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
Kiadis Pharma LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
ROVI Laboratorios Farmaceuticos RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Stellar Biotechnologies and Neovacs Announce Formation of New Company Neostell ...

Tue, 19 Jul 2016 12:00:00 GMT

Neovacs Signs a Strategic Partnering Agreement With the Korean Company CKD ...

Tue, 15 Dec 2015 07:15:23 GMT

Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships

Thu, 23 Jun 2016 15:11:15 GMT

Stellar Board Member and Pharma Expert to Join Executive Team

Mon, 24 Oct 2016 11:26:15 GMT

Week In Review: BioSense Signs $68 Million China Deal With Neovacs For ...

Sun, 26 Feb 2017 09:33:45 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2014A 0.2 (9.6) (9.8) (31.6) N/A N/A
2015A 1.2 (11.2) (11.4) (27.3) N/A N/A
2016E 0.2 (16.4) (16.5) (30.0) N/A N/A
2017E 0.0 (14.7) (14.8) (23.0) N/A N/A

Last updated on 22/03/2017

Investment summary

Neovacs is running a Phase IIb trial on its lead immunotherapy project, IFN-Kinoid (IFN-K) for lupus. Edison now expects the results from end of 2017. A deal has been signed with BioSense Global LLC for IFN alpha Kinoid to treat lupus and dermatomyositis in China, worth up to €65m in upfront and milestone payments plus double-digit sales royalties. Assuming trial success, CKD, the Korean partner, may start sales in 2018. Delays to the trial might cause the CKD €1.8m payment expected in 2017 to slip into 2018. An independent review recommended that the trial should continue. Cash in June 2015 was €9.2m.

Last updated on 04/04/2017

Industry outlook

There is a programme in dermatomyositis (DM), an orphan skin and muscular condition that might start in 2017. Neovacs plans to evaluate INF Kinoid in Type 1 diabetes, has a new academic collaboration and has gained positive preclinical data; trials may start in H1 2018. VEGF-Kinoid for cancer and AMD could start Phase I in H117. Neovacs will produce IFN with 3P Biopharmaceuticals.

Last updated on 04/04/2017

Key management

Jean-Jacques Bertrand, Chairman
Miguel Sieler, CEO

Company address

3-5 impasse Reille
75014 Paris
France
33 (0)1 53 10 93 00
View website